Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 951-961

  Nautiyal, Jyoti ^a,b,c   Banerjee, Sanjeev ^b,c   Kanwar, Shailender S ^a,c   Yu, Yingjie ^a,c   Patel, Bhaumik B ^a,b,c   Sarkar, Fazlul H ^b,c   Majumdar, Adhip P N ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cell invasion and angiogenesis; cell signaling; combination therapy; synergistic interactions; tumor regression

Indexed keywords

CURCUMIN; DASATINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLONIC NEOPLASMS; CURCUMIN; DRUG SYNERGISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL NEOPLASMS; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES; UMBILICAL VEINS;

EID: 78650624633     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25410     Document Type: Article

References (55)

1. Wils J, O'Dwyer P, Labianca R,. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 2001; 12: 13-22.
2. McCarty MF,. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 2004; 3: 349-80.
3. Harari PM, Huang SM,. Modulation of molecular targets to enhance radiation. Clin Cancer Res 2000; 6: 323-5.
4. Messa C, Russo F, Caruso MG, Di Leo A,. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-9.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N,. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
6. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ,. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995; 108: 564-80.
7. Malecka-Panas E, Kordek R, Biernat W, Tureaud J, Liberski PP, Majumdar AP,. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 1997; 44: 435-40.
8. Relan NK, Saeed A, Ponduri K, Fligiel SE, Dutta S, Majumdar AP,. Identification and evaluation of the role of endogenous tyrosine kinases in azoxymethane induction of proliferative processes in the colonic mucosa of rats. Biochim Biophys Acta 1995; 1244: 368-76.
9. Chen X, Yeung TK, Wang Z,. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277: 757-63.
10. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP,. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002; 123: 1191-204.
11. Frame MC,. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114-30.
12. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D,. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-33.
13. Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-58.
14. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM,. Discovery of N-(2-chloro-6-methyl-phenyl)-2- (6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61.
15. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL,. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
16. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41. (Pubitemid 43882349)
17. Johnson FM, Saigal B, Talpaz M, Donato NJ,. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 6924-32.
18. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R,. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-89.
19. Lind JS, Herder GJ, Smit EF,. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis]. Ned Tijdschr Geneeskd 2008; 152: 928-32.
20. Liu B, Fang M, Lu Y, Mills GB, Fan Z,. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 2001; 85: 303-11.
21. Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y,. Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull (Tokyo) 1985; 33: 1725-8.
22. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH,. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 1992; 13: 2183-6.
23. Rao CV, Rivenson A, Simi B, Reddy BS,. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995; 55: 259-66.
24. Rao CV, Simi B, Reddy BS,. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993; 14: 2219-25. (Pubitemid 23335173)
25. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ,. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002; 11: 535-40.
26. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
27. Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP,. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005; 4: 435-42.
28. Reddy S, Rishi AK, Xu H, Levi E, Sarkar FH, Majumdar AP,. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer 2006; 55: 185-94.
29. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, Majumdar AP,. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 2008; 122: 267-73.
30. Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP,. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Letters, 2009; 283: 143-51.
31. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH,. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818-26.
32. Schmelz EM, Xu H, Sengupta R, Du J, Banerjee S, Sarkar FH, Rishi AK, Majumdar AP,. Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. Cancer Res 2007; 67: 5389-96.
33. Levi E, Mohammad R, Kodali U, Marciniak D, Reddy S, Aboukameel A, Sarkar FH, Kucuk O, Rishi AK, Majumdar AP,. EGF-receptor related protein causes cell cycle arrest and induces apoptosis of colon cancer cells in vitro and in vivo. Anticancer Res 2004; 24: 2885-91.
34. Marciniak DJ, Moragoda L, Mohammad RM, Yu Y, Nagothu KK, Aboukameel A, Sarkar FH, Adsay VN, Rishi AK, Majumdar AP,. Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology 2003; 124: 1337-47.
35. Datta SR, Brunet A, Greenberg ME,. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
36. Kunnumakkara AB, Anand P, Aggarwal BB,. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
37. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC,. Multiple biological activities of curcumin: a short review. Life Sci 2006; 78: 2081-87.
38. Rishi AK, Parikh R, Wali A, Durko L, Zhang L, Yu Y, Majumdar AP,. EGF receptor-related protein (ERRP) inhibits invasion of colon cancer cells and tubule formation by endothelial cells in vitro. Anticancer Res 2006; 26: 1029-37.
39. Moser AR, Pitot HC, Dove WF,. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-4.
40. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE,. Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-72.
41. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM,. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 2007; 6: 1962-72.
42. Johnson FM, Saigal B, Tran H, Donato NJ,. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007; 13: 4233-44.
43. Howells LM, Mitra A, Manson MM,. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007; 121: 175-83.
44. Goel A, Boland CR, Chauhan DP,. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111-8.
45. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ,. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445-51.
46. Moghal N, Sternberg PW,. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 1999; 11: 190-6.
47. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr,. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-9.
48. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R,. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005; 104: 879-90.
49. Serrels A, Macpherson IRJ, Evans TRJ, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG,. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther 2006; 5: 3014-22.
50. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim S-J, Wang Z, Gallick GE,. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-33.
51. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R,. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res 2007; 67: 2800-808.
52. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB,. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006; 66: 5542-8.
53. Barnes CJ, Lee M,. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998; 114: 873-7.
54. Aggarwal BB, Ichikawa H, Garodia P, Weerasinghe P, Sethi G, Bhatt ID, Pandey MK, Shishodia S, Nair MG,. From traditional ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006; 10: 87-118.
55. Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, Li J, Dou QP, Sarkar FH,. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009; 26: 2438-45.